## Shinya S Suzuki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4678968/publications.pdf

Version: 2024-02-01

		236925	302126
129	2,127	25	39
papers	citations	h-index	g-index
130	130	130	2937
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Two-year outcomes of more than 30Â000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 202-213.	4.0	47
2	Association of Low Body Weight with Clinical Outcomes in Elderly Atrial Fibrillation Patients Receiving Apixaban—J-ELD AF Registry Subanalysis. Cardiovascular Drugs and Therapy, 2022, 36, 691-703.	2.6	3
3	Different Determinants of the Recurrence of Atrial Fibrillation and Adverse Clinical Events in the Mid-Term Period After Atrial Fibrillation Ablation. Circulation Journal, 2022, 86, 233-242.	1.6	16
4	Impact of sinus rhythm maintenance on major adverse cardiac and cerebrovascular events after catheter ablation of atrial fibrillation: insights from AF frontier ablation registry. Heart and Vessels, 2022, 37, 327-336.	1.2	5
5	Glasgow prognostic score can be a prognostic indicator after percutaneous coronary intervention: a two-center study in Japan. Heart and Vessels, 2022, 37, 903-910.	1.2	3
6	Identifying patients with atrial fibrillation during sinus rhythm on ECG: Significance of the labeling in the artificial intelligence algorithm. IJC Heart and Vasculature, 2022, 38, 100954.	1.1	3
7	Newly developed modified diluted prothrombin time reagent: A multi-centre validation in patients with non-valvular atrial fibrillation under direct oral anticoagulant therapy. Thrombosis Research, 2022, 210, 87-90.	1.7	2
8	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Circulation Journal, 2022, 86, 1790-1924.	1.6	49
9	Impact of anemia on the clinical outcomes in elderly patients with atrial fibrillation receiving apixaban: J-ELD AF registry subanalysis. IJC Heart and Vasculature, 2022, 40, 100994.	1.1	2
10	Frailty and outcomes in older adults with non-valvular atrial fibrillation from the ANAFIE registry. Archives of Gerontology and Geriatrics, 2022, 101, 104661.	3.0	11
11	Impact of Previous Stroke on Clinical Outcome in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Registry. Stroke, 2022, 53, 2549-2558.	2.0	4
12	Clinical outcomes of ablation versus non-ablation therapy for atrial fibrillation in Japan: analysis of pooled data from the AF Frontier Ablation Registry and SAKURA AF Registry. Heart and Vessels, 2021, 36, 549-560.	1.2	13
13	Clinical outcomes according to dose reduction criteria of apixaban in Japanese elderly patients with atrial fibrillation: J-ELD AF Registry subanalysis. Heart and Vessels, 2021, 36, 1035-1046.	1.2	O
14	Relationship between resting 12-lead electrocardiogram and all-cause death in patients without structural heart disease: Shinken Database analysis. BMC Cardiovascular Disorders, 2021, 21, 83.	1.7	2
15	Prediction of current and new development of atrial fibrillation on electrocardiogram with sinus rhythm in patients without structural heart disease. International Journal of Cardiology, 2021, 327, 93-99.	1.7	8
16	Predictors for a high apixaban level in elderly patients with atrial fibrillation prescribed reduced dose of apixaban. European Journal of Clinical Pharmacology, 2021, 77, 1757-1758.	1.9	3
17	Decline in eGFR over time and incidence of cardiovascular events: Shinken database analysis. Journal of Cardiology, 2021, 77, 626-633.	1.9	2
18	Left atrial dimension and ischemic stroke in patients with and without atrial fibrillation. Heart and Vessels, 2021, 36, 1861-1869.	1.2	6

#	Article	IF	CITATIONS
19	A Novel Risk Stratification System for Ischemic Stroke in Japanese Patients With Non-Valvular Atrial Fibrillation. Circulation Journal, 2021, 85, 1254-1262.	1.6	14
20	Relationship between number of medications and incidence of falls or bone fracture in elderly patients with nonâ€valvular atrial fibrillation: Shinken database analysis. Geriatrics and Gerontology International, 2021, 21, 802-809.	1.5	3
21	Clinical Outcomes of Very Elderly Patients With Atrial Fibrillation Receiving Onâ€label Doses of Apixaban: Jâ€ELD AF Registry Subanalysis. Journal of the American Heart Association, 2021, 10, e021224.	3.7	4
22	Current status of oral anticoagulant adherence in Japanese patients with atrial fibrillation: A claims database analysis. Journal of Cardiology, 2021, 78, 150-156.	1.9	14
23	Prediction of biological age and all-cause mortality by 12-lead electrocardiogram in patients without structural heart disease. BMC Geriatrics, 2021, 21, 460.	2.7	15
24	Association between number of medications and mortality among older adult patients in a specialized cardiology hospital. Geriatrics and Gerontology International, 2021, 21, 985-995.	1.5	0
25	Current Status of Catheter Ablation for Atrial Fibrillation in Japan. International Heart Journal, 2021, 62, 997-1004.	1.0	0
26	Identifying risk patterns in older adults with atrial fibrillation by hierarchical cluster analysis: A retrospective approach based on the risk probability for clinical events. IJC Heart and Vasculature, 2021, 37, 100883.	1.1	7
27	II. Atrial Fibrillation. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 722-728.	0.0	0
28	Relationship between age and maximal heart rate in atrial fibrillation. European Journal of Preventive Cardiology, 2020, 27, 780-782.	1.8	1
29	Creatinine clearance and inappropriate dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. Heart and Vessels, 2020, 35, 110-117.	1.2	8
30	A case of female Fabry disease revealed by renal biopsy. CEN Case Reports, 2020, 9, 24-29.	0.9	2
31	Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7). Heart and Vessels, 2020, 35, 409-416.	1.2	5
32	A Simple Formula for Predicting the Maintenance Dose of Warfarin with Reference to the Initial Response to Low Dosing at an Outpatient Clinic. Internal Medicine, 2020, 59, 29-35.	0.7	1
33	Myocardial bridging is an independent predictor of positive spasm provocation testing by intracoronary ergonovine injections: a retrospective observational study. Heart and Vessels, 2020, 35, 474-486.	1.2	14
34	A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (Jâ€ELD AF Registry). Clinical Cardiology, 2020, 43, 251-259.	1.8	23
35	A novel and simple scoring system for assessing the indication for catheter ablation in patients with atrial fibrillation: The HEALâ€AF Score. Journal of Arrhythmia, 2020, 36, 997-1006.	1.2	2
36	Decline of estimated glomerular filtration rate has triphasic changes according to age. Geriatrics and Gerontology International, 2020, 20, 844-846.	1.5	1

#	Article	IF	CITATIONS
37	Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis. European Journal of Clinical Pharmacology, 2020, 76, 1111-1124.	1.9	12
38	Role of dipstick proteinuria for predicting cardiovascular events: a Japanese cardiovascular hospital database analysis. Heart and Vessels, 2020, 35, 1256-1269.	1.2	7
39	Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry subanalysis. American Heart Journal, 2020, 223, 23-33.	2.7	8
40	Association between bisoprolol plasma concentration and worsening of heart failure: (CVI ARO 6). Drug Metabolism and Pharmacokinetics, 2020, 35, 228-237.	2.2	1
41	Differences in treatment and prognosis by the experience of falls or bone fracture in elderly patients with atrial fibrillation. Heart and Vessels, 2020, 35, 1234-1242.	1.2	1
42	Exploratory Analysis of Circulating miRNA Signatures in Atrial Fibrillation Patients Determining Potential Biomarkers to Support Decision-Making in Anticoagulation and Catheter Ablation. International Journal of Molecular Sciences, 2020, 21, 2444.	4.1	13
43	Risk Factors Associated With Ischemic Stroke in Japanese Patients With Nonvalvular Atrial Fibrillation. JAMA Network Open, 2020, 3, e202881.	5.9	39
44	Analysis of bioMARKer Distribution and Individual Reproducibility Under Rivaroxaban Treatment in Japanese Patients with Non-Valvular Atrial Fibrillation (R-MARK Study, CVI ARO2). International Heart Journal, 2020, 61, 695-704.	1.0	2
45	Clinical Outcomes of Off-Label Underdosing of Direct Oral Anticoagulants After Ablation for Atrial Fibrillation. International Heart Journal, 2020, 61, 1165-1173.	1.0	10
46	A Study of Validation in Atrial Fibrillation Detection with a Wristwatch-type Pulse Wave Monitoring Device: Comparison with Holter Monitoring Device 4°CVI ARO 3 study 4%. Japanese Journal of Electrocardiology, 2020, 40, 207-216.	0.0	2
47	Current situations of and how to deal with polypharmacy in non-valvular atrial fibrillation. Japanese Journal of Thrombosis and Hemostasis, 2020, 31, 591-598.	0.1	0
48	Association Between Dose and Plasma Concentration of Bisoprolol in Patients with Heart Failure (CVI) Tj ETQq0 (	0 0 rgBT /0	Overlock 10 Ti
49	Seasonal Variations in the Incidence of Ischemic Stroke, Extracranial and Intracranial Hemorrhage in Atrial Fibrillation Patients. Circulation Journal, 2020, 84, 1701-1708.	1.6	1
50	Eleven-year temporal trends of clinical characteristics and long-term outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndrome in the Shinken database. Heart and Vessels, 2019, 34, 199-207.	1.2	5
51	External suture annuloplasty for mild to moderate and moderate aortic regurgitation due to an isolated type Ic lesion. General Thoracic and Cardiovascular Surgery, 2019, 67, 855-860.	0.9	2
52	Current Status and Clinical Outcomes of Oral Anticoagulant Discontinuation After Ablation for Atrial Fibrillation in Japan ― Findings From the AF Frontier Ablation Registry ―. Circulation Journal, 2019, 83, 2418-2427.	1.6	16
53	Comparison of risk models for mortality and cardiovascular events between machine learning and conventional logistic regression analysis. PLoS ONE, 2019, 14, e0221911.	2.5	37
54	Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI) Tj ETQq0 0 0	rg <b>B1</b> /Ove	erlosek 10 Tf 50

#	Article	IF	Citations
55	Impact of Atrial Fibrillation on Falls in Older Patients: Which is a Problem, Existence or Persistence?. Journal of the American Medical Directors Association, 2019, 20, 765-769.	2.5	5
56	The predictive role of E/e $\hat{a}$ $\in$ 2 on ischemic stroke and atrial fibrillation in Japanese patients without atrial fibrillation. Journal of Cardiology, 2018, 72, 33-41.	1.9	10
57	Relationship between the prognostic value of ventilatory efficiency and age in patients with heart failure. European Journal of Preventive Cardiology, 2018, 25, 731-739.	1.8	13
58	An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1). Drug Metabolism and Pharmacokinetics, 2018, 33, 188-193.	2.2	16
59	Variable prognostic value of blood pressure response to exercise. Journal of Cardiology, 2018, 71, 31-35.	1.9	7
60	Impact of electrophysiological and pharmacological noninducibility following pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation. Journal of Arrhythmia, 2018, 34, 501-510.	1.2	5
61	Prognostic value of the heart rate profile during exercise in patients with atrial fibrillation. European Journal of Preventive Cardiology, 2018, 25, 1634-1641.	1.8	7
62	Predictors of International Normalized Ratio Variability in Patients With Atrial Fibrillation Under Warfarin Therapy. Circulation Journal, 2018, 82, 39-45.	1.6	8
63	Response of prothrombin time to rivaroxaban in Japanese patients with non-valvular atrial fibrillation: Characteristics of 5 representative reagents in Japan (CVI ARO 1). Thrombosis Research, 2017, 150, 73-75.	1.7	9
64	Impact of BNP level and peak VO2 on future heart failure events: comparison between sinus rhythm and atrial fibrillation. Heart and Vessels, 2017, 32, 428-435.	1.2	6
65	Effects of Smoking on Ischemic Stroke, Intracranial Hemorrhage, and Coronary Artery Events in Japanese Patients With Non-Valvular Atrial Fibrillation. International Heart Journal, 2017, 58, 506-515.	1.0	13
66	Left Atrial Remodeling Assessed by Transthoracic Echocardiography Predicts Left Atrial Appendage Flow Velocity in Patients With Paroxysmal Atrial Fibrillation. International Heart Journal, 2016, 57, 177-182.	1.0	13
67	The predictive value of the borderline ankle-brachial index for long-term clinical outcomes: An observational cohort study. Atherosclerosis, 2016, 250, 69-76.	0.8	22
68	The relationship between resting heart rate and peak VO <sub>2</sub> : A comparison of atrial fibrillation and sinus rhythm. European Journal of Preventive Cardiology, 2016, 23, 1429-1436.	1.8	21
69	Nine-Year Trend of Anticoagulation Use, Thromboembolic Events, and Major Bleeding in Patients With Non-Valvular Atrial Fibrillation – Shinken Database Analysis –. Circulation Journal, 2016, 80, 639-649.	1.6	45
70	DIFFERENCE IN THE IMPACT OF BNP AND PEAK VO2 ON FUTURE HEART FAILURE EVENTS BETWEEN ATRIAL FIBRILLATION AND SINUS RHYTHM. Journal of the American College of Cardiology, 2016, 67, 720.	2.8	0
71	Prognostic significance of exercise capacity and resting heart rate: Comparison between atrial fibrillation and sinus rhythm. International Journal of Cardiology, 2016, 203, 561-563.	1.7	4
72	Heart Failure Admission in Winter as an Independent Predictor for Early Rehospitalization after Discharge. Journal of Cardiac Failure, 2015, 21, S148.	1.7	0

#	Article	IF	Citations
73	ABO Blood Type and Response of Activated Partial Thromboplastin Time to Dabigatran in Nonvalvular Atrial Fibrillation Patients. Circulation Journal, 2015, 79, 2274-2277.	1.6	2
74	Incidence of Ischemic Stroke in Japanese Patients With Atrial Fibrillation Not Receiving Anticoagulation Therapy. Circulation Journal, 2015, 79, 432-438.	1.6	108
75	Incidence and Predictors of Rehospitalization of Acute Heart Failure Patients. International Heart Journal, 2015, 56, 219-225.	1.0	29
76	The prognostic impact of worsening renal function in Japanese patients undergoing percutaneous coronary intervention with acute coronary syndrome. Journal of Cardiology, 2015, 66, 326-332.	1.9	14
77	Relation between frequency of activated partial prothrombin time measurements and clinical outcomes in patients after initiation of dabigatran: A twoâ€center cooperative study. Journal of Arrhythmia, 2015, 31, 18-21.	1.2	2
78	Clinical Significance of a Spiral Phenomenon in the Plot of CO2 Output Versus O2 Uptake During Exercise in Cardiac Patients. American Journal of Cardiology, 2015, 115, 691-696.	1.6	0
79	Association between smoking habits and the first-time appearance of atrial fibrillation in Japanese patients: Evidence from the Shinken Database. Journal of Cardiology, 2015, 66, 73-79.	1.9	26
80	Antiplatelet therapy in Japanese patients with atrial fibrillation without oral anticoagulants: Pooled analysis of Shinken Database, J-RHYTHM registry and Fushimi AF registry. International Journal of Cardiology, 2015, 190, 344-346.	1.7	3
81	Enlargement of the left atrium is associated with increased infiltration of immune cells in patients with atrial fibrillation who had undergone surgery. Journal of Arrhythmia, 2015, 31, 78-82.	1.2	18
82	Geriatric nutritional risk index in hospitalized heart failure patients. International Journal of Cardiology, 2015, 181, 213-215.	1.7	38
83	Impact of atrial fibrillation on longâ€ŧerm clinical outcomes in outpatients with heart failure. Journal of Arrhythmia, 2014, 30, 186-191.	1.2	0
84	Presentations and outcomes of patients with acute decompensated heart failure admitted in the winter season. Journal of Cardiology, 2014, 64, 470-475.	1.9	10
85	Long-term incidence and prognostic factors of the progression of new coronary lesions in Japanese coronary artery disease patients after percutaneous coronary intervention. Heart and Vessels, 2014, 29, 437-442.	1.2	21
86	Impact of aging on the clinical outcomes of Japanese patients with coronary artery disease after percutaneous coronary intervention. Heart and Vessels, 2014, 29, 156-164.	1,2	34
87	Prevalence and the long-term prognosis of functional mitral regurgitation in Japanese patients with symptomatic heart failure. Heart and Vessels, 2014, 29, 801-807.	1.2	18
88	Coronary artery diseases in Japanese patients with nonvalvular atrial fibrillation. Journal of Cardiology, 2014, 63, 123-127.	1.9	19
89	Functional mitral regurgitation and left ventricular systolic dysfunction in the recent era of cardiovascular clinical practice, an observational cohort study. Hypertension Research, 2014, 37, 1082-1087.	2.7	14
90	A case of premature ventricular contractions originating from the papillary muscle in the right ventricle. Journal of Arrhythmia, 2014, 30, 192-196.	1.2	0

#	Article	IF	CITATIONS
91	Relationship between cardiopulmonary exercise testing parameters and heart failure risk (H2ARDD) Tj ETQq1	1 0.784314 rg	gBT /Overlo
92	Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. Heart and Vessels, 2014, 29, 21-28.	1.2	28
93	Impact of Pulmonary Vein Isolation on Left Bundle Branch Block Following Tachycardia-induced Cardiomyopathy in a Patient with Persistent Atrial Fibrillation. Internal Medicine, 2014, 53, 721-724.	0.7	2
94	Progression to the Persistent Form in Asymptomatic Paroxysmal Atrial Fibrillation. Circulation Journal, 2014, 78, 1121-1126.	1.6	29
95	Rivaroxaban in Clinical Practice for Atrial Fibrillation With Special Reference to Prothrombin Time. Circulation Journal, 2014, 78, 763-766.	1.6	8
96	Alcohol and Atrial Fibrillation. Circulation Journal, 2014, 78, 839-840.	1.6	2
97	Role of arterial stiffness and impaired renal function in the progression of new coronary lesions after percutaneous coronary intervention. Cardiovascular Intervention and Therapeutics, 2013, 28, 56-62.	2.3	16
98	Estimated glomerular filtration rate and proteinuria are associated with persistent form of atrial fibrillation: Analysis in Japanese patients. Journal of Cardiology, 2013, 61, 53-57.	1.9	19
99	"Blue letter effects― Changes in physicians' attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan. Journal of Cardiology, 2013, 62, 366-373.	1.9	13
100	Obesity paradox in Japanese patients after percutaneous coronary intervention: An observation cohort study. Journal of Cardiology, 2013, 62, 18-24.	1.9	50
101	Clinical characteristics and long-term clinical outcomes of Japanese heart failure patients with preserved versus reduced left ventricular ejection fraction: A prospective cohort of Shinken Database 2004–2011. Journal of Cardiology, 2013, 62, 102-109.	1.9	34
102	Usefulness of Frequent Supraventricular Extrasystoles and a High CHADS2 Score to Predict First-Time Appearance of Atrial Fibrillation. American Journal of Cardiology, 2013, 111, 1602-1607.	1.6	59
103	Effects of Smoking Habit on the Prevalence of Atrial Fibrillation in Japanese Patients With Special Reference to Sex Differences. Circulation Journal, 2013, 77, 2948-2953.	1.6	16
104	Recent Characteristics and Outcomes of Japanese Stable Angina Pectoris After Percutaneous Coronary Intervention. International Heart Journal, 2013, 54, 335-340.	1.0	11
105	Gender-Specific Relationship Between Serum Uric Acid Level and Atrial Fibrillation Prevalence. Circulation Journal, 2012, 76, 607-611.	1.6	63
106	Dabigatran in Clinical Practice for Atrial Fibrillation With Special Reference to Activated Partial Thromboplastin Time. Circulation Journal, 2012, 76, 755-757.	1.6	30
107	Distribution of First-Detected Atrial Fibrillation Patients Without Structural Heart Diseases in Symptom Classifications. Circulation Journal, 2012, 76, 1020-1023.	1.6	25
108	A New Scoring System for Evaluating the Risk of Heart Failure Events in Japanese Patients With Atrial Fibrillation. American Journal of Cardiology, 2012, 110, 678-682.	1.6	36

#	Article	IF	Citations
109	Relationship between 24-h Holter recordings and clinical outcomes in patients with permanent atrial fibrillation. Journal of Cardiology, 2012, 60, 42-46.	1.9	5
110	Role of cardiopulmonary dysfunction and left atrial remodeling in development of acute decompensated heart failure in chronic heart failure with preserved left ventricular ejection fraction. Journal of Cardiology, 2012, 59, 359-365.	1.9	18
111	Statin Treatment for Patients With Paroxysmal Atrial Fibrillation A J-RHYTHM Substudy. International Heart Journal, 2011, 52, 103-106.	1.0	7
112	"Cholesterol Paradox" in Atrial Fibrillation. Circulation Journal, 2011, 75, 2749-2750.	1.6	24
113	Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease. Journal of Cardiology, 2011, 57, 172-180.	1.9	17
114	Recent mortality of Japanese patients with atrial fibrillation in an urban city of Tokyo. Journal of Cardiology, 2011, 58, 116-123.	1.9	61
115	Comparison of Antiarrhythmics Used in Patients With Paroxysmal Atrial Fibrillation:. Circulation Journal, 2010, 74, 71-76.	1.6	11
116	Body Size and Atrial Fibrillation in Japanese Outpatients. Circulation Journal, 2010, 74, 66-70.	1.6	24
117	Effects of Nicorandil on Cardiovascular Events in Patients With Coronary Artery Disease in The Japanese Coronary Artery Disease (JCAD) Study. Circulation Journal, 2010, 74, 503-509.	1.6	60
118	Impact of Drug Alteration to Maintain Rhythm Control in Paroxysmal Atrial Fibrillation - Subanalysis From J-RHYTHM Study Circulation Journal, 2010, 74, 870-875.	1.6	8
119	Clinical outcome after acute coronary syndrome in Japanese patients: An observational cohort study. Journal of Cardiology, 2010, 55, 69-76.	1.9	25
120	Heart failure with preserved versus reduced left ventricular systolic function: A prospective cohort of Shinken Database 2004–2005. Journal of Cardiology, 2010, 55, 108-116.	1.9	19
121	Brachial-ankle pulse wave velocity as a risk stratification index for the short-term prognosis of type 2 diabetic patients with coronary artery disease. Hypertension Research, 2010, 33, 1018-1024.	2.7	79
122	Impact of reduced renal function on prognosis in Japanese patients with coronary artery disease: a prospective cohort of Shinken Database 2007. Hypertension Research, 2009, 32, 920-926.	2.7	14
123	Treatment strategy and clinical outcome in Japanese patients with atrial fibrillation. Heart and Vessels, 2009, 24, 287-293.	1.2	17
124	Prevalence and Prognosis of Patients With Heart Failure in Tokyo. International Heart Journal, 2009, 50, 609-625.	1.0	12
125	Prevalence and Prognosis of Patients With Atrial Fibrillation in Japan. Circulation Journal, 2008, 72, 914-920.	1.6	86
126	Selected ventriculoplasty for idiopathic dilated cardiomyopathy with advanced congestive heart failure: midterm results and risk analysis. European Journal of Cardio-thoracic Surgery, 2007, 32, 912-916.	1.4	23

#	Article	IF	CITATIONS
127	Incidence of Major Bleeding Complication of Warfarin Therapy in Japanese Patients With Atrial Fibrillation. Circulation Journal, 2007, 71, 761-765.	1.6	89
128	Characteristics of Congestive Heart Failure Accompanied by Atrial Fibrillation With Special Reference to Tachycardia-Induced Cardiomyopathy. Circulation Journal, 2007, 71, 936-940.	1.6	57
129	A Case of Cholesterol Embolism Confirmed by Skin Biopsy and Successfully Treated with Statins and Steroids. American Journal of the Medical Sciences, 2006, 331, 280-283.	1.1	14